We have reported the purification and characterization of a protein that behaves as a liver growth factor, showing activity either in vivo or in vitro [Diaz-Gil et al. (1986) Biochem. J. 235,[49][50][51][52][53][54][55]. In the present paper, we identify this liver growth factor (LGF) as an albumin-bilirubin complex. This conclusion is supported by the results of chemical and spectroscopic characterization of this protein as well as by experiments in vivo. Incubation of albumin isolated from normal rats with bilirubin at several bilirubin/albumin molar ratios (r) resulted (when r = 1 or 2) in a complex with liver DNA synthesis promoter activity identical with that of LGF. The exact amount of bilirubin bound to albumin was assessed by fluorescence and c.d. spectra. This albumin-bilirubin complex showed the same dose-dependence profile as LGF either at low or high dose of protein injected per mouse. Both LGF and albumin-bilirubin complex produced similar increases in the mitotic index of mouse hepatocytes in vivo. A new mechanism for the onset of the hepatic regenerative process is proposed.
INTRODUCTION
We recently reported the purification of a 64000-Mr protein from plasma of partially hepatectomized rats which exhibits hepatic promoter activity both in vivo and in vitro (Diaz-Gil et al., 1986a) . The injection of this protein into mice at nanogram doses (up to 150 ng/mouse) increases [3H] thymidine uptake by liver DNA, producing an increase in the mitotic index of hepatocytes. In primary liver cell cultures, it produces an increase in the uptake of [3H] thymidine into DNA in the range of 1-10 ng/ml, as well as an increase, immediately upon addition, in the uptake of 22Na+. In view of the activity exhibited by this protein and to avoid confusing its context with other areas of research, we will refer to this protein hereafter as 'liver growth factor' (LGF).
The present paper deals with the characterization of this LGF.
MATERLILS AND METHODS Materials
Chemicals were purchased from Sigma, Bio-Rad, Cultek, Merck and Pharmacia. [3H]Thymidine (specific radioactivity 20 Ci/mmol) was from New England Nuclear.
Wistar rats (90-110 g body wt.) were 70% hepatectomized by the method of Higgins & Anderson (1931) . Plasma was obtained from heparinized blood of normal or hepatectomized rats by cardiac puncture. Plasma samples were freeze-dried and kept at 4°C until use. LGF purification and analysis of activity
The purification of LGF was carried out as previously described (Diaz-Gil et al., 1986a) . Commercial rat serum albumin (fraction V from Sigma) was purified by a three-step procedure very similar to that used for LGF purification: chromatography on Sephadex G-75, DEAE-cellulose and hydroxyapatite. We refer to this as purified serum albumin. Following the same strategy, we purified albumin from plasma of either normal or hepatectomized rats. We call these fractions F 121(N) and F 121(PH), respectively. The determination of the activity in terms of DNA synthesis promoter was carried out in mice, as previously indicated (Diaz-Gil et al., 1986a) . For the extraction of DNA, the method of MacManus et al. (1972) was used; total DNA was determined by the method of Burton (1968) . Specific incorporation of [3H]thymidine into DNA was expressed as d.p.m./,g of DNA. Protein determination was performed by the method of Lowry et al. (1951) .
For experiments in vitro, hepatocytes from 150 g bodywt. Wistar rats were isolated by a collagenase perfusion technique (Bonney et al., 1974) . More details regarding the procedure followed to evaluate LGF activity are given in a previous publication (Diaz-Gil et al., 1986a calculations was 111.5, based on the amino acid composition of the protein (see below). Fluorescence spectra were obtained on a Perkin-Elmer MPF 44E spectrofluorimeter. Spectra were corrected for detector response. The protein solutions were filtered through a Millipore filter (0.5 gsm pore diameter) prior to the spectroscopic analysis, which was performed at 20 'C. The protein concentration for the spectroscopic calculations was determined by amino acid analysis.
Other analytical procedures SDS/polyacrylamide-gel electrophoresis was performed according to Laemmli (1980) . For mitotic index determination, the procedure of Morley & Kingdon (1973) was employed. The Ouchterlony immunodiffusion and immunoelectrophoresis experiments were carried out on agarose (1.5% solution with 35 mM-barbital buffer), using 65 mM-barbital, pH 8.6, as running buffer.
Performic acid oxidized proteins (Hirs, 1956 ) were digested with trypsin at 100:1 protein: enzyme weight ratio for 4 h at 37 'C in 0.2 M-NH4HCO3, pH 8.0. The resulting peptides were separated by using an Ultrasphere ODS column (4.5 mm x 250 mm; 5 #m particle size).
The protein samples were hydrolysed at 108 'C (for 24, 48 and 96 h) with constant-boiling HCI containing 0.1 % (w/v) phenol, in evacuated and sealed tubes. Hydrolysates were analysed on a Durrum model D-500 amino acid analyser. Albumin-bilirubin complex formation Bilirubin was purchased from Signa. Its purity was checked by the procedure of McDonagh & Assisi (1971) . (Hirs, 1956 Binding of bilirubin to albumin was carried out by the method of Wooley & Hunter (1970) . In experiments where bilirubin was injected alone, it was previously incubated in the same conditions described above for bilirubin-albumin samples.
RESULTS

Protein-chemical similarities between LGF and serum albumin
The amino acid compositions of albumin and LGF are very similar (Table 1 ). The similarity between the two proteins is also observed by comparing their tryptic maps (Fig. 1) . The u.v.-absorbance spectra of purified serum albumin and LGF are coincident. The fluorescence emission spectra for excitation at 295 nm are almost coincident. Only slight differences are observed in the c.d. spectra of the two proteins in the near-u.v. region, although no differences are observed at the level of the secondary structure (Fig. 2) . The secondary structure of
LGF would be composed of 59% a-helix, 17% f-structure and 24% aperiodic conformation, with an average number of 10 residues per helical segment, based on the far-u.v. c.d. spectrum and using the reference parameters of Cheng et al. (1974) . The immunodiffusion and immunoelectrophoresis experiments indicate that purified serum albumin and LGF have the same antigenic determinants [a commercial preparation of anti-(rat serum albumin) serum from rabbit (Nordic Immunological Reagents) was used]. All of these results strongly suggest that this liver growth factor contains, or is a form of, albumin. Thus, we studied the potential effect of both commercial and purified rat serum albumin, F 121(N), as liver growth factors, finding no such activity in these proteins. However, albumin purified from partially hepatectomized rats, F 121(PH), exhibits liver growth factor activity both in vivo and in vitro. The chemical analysis of F 121(PH) revealed the identity between this protein and LGF. Thus, we will refer to both of them simply as LGF. All of these observations corroborate the supposition that LGF is a special kind of albumin present in plasma of partially hepatectomized rats. Serum albumin-bilirubin complex prepared in vitro is a liver growth factor Another feasible explanation is that the LGF isolated could simply be albumin with a very-low-Mr ligand, X.
As a further development of this hypothesis, the hypothetical X ligand could be the true liver growth factor, appearing in situations of partial hepatectomy, and absent from normal rats. We considered the possibility that bilirubin be responsible for the liver growth factor activity of albumin from plasma of partially hepatectomized rats, thus implying that bilirubin would be a component of LGF.
To check this possibility, we performed an experiment incubating albumin from normal rats, F 121(N), with increasing quantities of bilirubin. We adjusted the concentrations of F 121(N) and bilirubin to reach bilirubin/albumin molar ratios (r) of 0.1, 0.5, 0.8, 1, 2, 3, 4 and 10. After the incubation period (see the Materials and methods section), we checked their activity in vivo by injection into mice at doses of 150 ng of protein per mouse in every case. Samples with r = 1 and 2 showed DNA synthesis promoting activity ( Table  2 ). The increase in [3H]thymidine uptake was very similar to that corresponding to LGF alone at the same amount of protein injected per mouse. When r was increased to values of 3, 4 or 10, or decreased to 0.8, 0.5 or 0.1, a lower DNA synthesis stimulation was detected.
As controls for this experiment, F 121(N) or bilirubin alone were injected, revealing a lack of any stimulatory Vol. 243 effect. In the case of bilirubin alone, the same total quantity was injected as in experiments with bilirubin/ albumin ratios of 1 and 2 (1.57 or 3.15 ng/mouse, respectively), and no increases were observed (Table 2) . Furthermore, bilirubin was injected alone at doses of Table 3 .
When both ellipticity values at 400 and 452 nm are plotted versus protein/bilirubin molar ratio, a saturation curve is obtained; however, two inflection points can be observed (results not shown). These factors could be interpreted in terms of two different contributions to the c.d. signal arising from bound bilirubin. It is known that albumin possesses two kinds of binding sites for bilirubin, one of high affinity and one or two of low affinity (Berde et al., 1979; Lavie & Blauer, 1979) . Although the percentage of bound bilirubin was estimated from the c.d. measurements (Table 3) , these data have not been considered in Fig. 3 . This Figure was designed only on the basis of the values obtained from the fluorescence determinations. In fact, the potential existence of two different contributions to the c.d. signal upon bilirubin binding could mask the calculation of the value obtained by extrapolation to a (protein/bilirubin)-zero value. Fig. 3 shows the liver growth factor activity of bilirubin-albumin complexes (at different bilirubin/ albumin ratios) versus the percentage of bound bilirubin. A plateau of maximal activity is reached and the specific incorporation detected on both sides of the plateau decreases. This result indicates that when bilirubin binds roughly between 26 and 33 % with respect to the albumin present, in terms of molar ratios, a maximum activity of the complex is attained.
The dose-dependence curve of the albumin-bilirubin complex was compared with that of LGF. Fig. 3 . Percentage of bilirubin bound to albumin necessary to form the liver growth factor Percentage of bound bilirubin (over total bilirubin incubated at several bilirubin/albumin molar ratios) was obtained from fluorescence spectra (Table 3) and specific  incorporation from Table 2 (see the Results section for details). DNA synthesis was similar to that produced by 300 ng of LGF or bilirubin complex alone (Fig. 4) . This experiment provides additional evidence for the identity of LGF and albumin-bilirubin complex. Previous results in our laboratory (results not shown) indicated that LGF also exhibits a peak of activity at milligram doses. In order to verify this behaviour for the albumin-bilirubin complex, we have performed the experiments in Finally, we have also measured the effect of albuminbilirubin complex (r = 1) on the mitotic index in mouse liver, comparing it with the corresponding values obtained with LGF (Table 4 ). The albumin-bilirubin complex mimics the previously reported increase in mitotic index provoked by injection of LGF (Diaz-Gil et al., 1986a) .
DISCUSSION
The appearance of liver growth factor activity in albumin after its binding to bilirubin could be the result of a conformational change that exposed to the exterior an active site of the albumin, sequestered in normal conditions (without a significant amount of bound bilirubin). In this respect, Taylor et al. (1975) (Beaven et al., 1973; Lavie & Blauer, 1979) . We suggest this possibility in this case owing to the slight differences detected between the c.d. spectra of LGF and albumin. hepatocyte could have multiple binding sites, in a similar fashion to that described for oestrogen receptors on human prostate (Ekman et al., 1983) .
The identification of LGF as an albumin-bilirubin complex suggests a new concept of the onset of the hepatic regeneration process. Immediately after partial hepatectomy, the albumin-bilirubin complex would be formed, producing a wave of liver regeneration. This albumin-bilirubin complex would disappear in the course of regeneration and, upon reaching normal liver size, would be undetectable (we were not able to detect LGF activity in normal rats). The biological role of this liver growth factor would be operative not only in situations of partial hepatectomy, but in cases of liver injury, when hepatocyte proliferation was required. Some facts seem to support this proposed model of the regeneration process. First, when ethanol is administered to rats at high doses (acute toxicity), there is no change in the synthesis of total liver protein, but a retention of newly synthesized albumin in the liver is detected (Morland, 1975; Baraona et al., 1980) . These authors feel that it could be due to an impairment of albumin secretion by hepatocytes, but an alternative explanation could lie in the uptake of newly synthesized albumin by hepatocytes in the form of LGF molecules. Second, in rats in which cirrhosis has been induced by injection of carbon tetrachloride/phenobarbitone (Courtoy et al., 1981) , a decreased serum albumin concentration is observed. These authors detected indirect evidence demonstrating that the rate of albumin synthesis per hepatocyte could even be increased. One possible explanation could be the uptake of part of the serum albumin by hepatocytes as LGF, producing a wave of regeneration. Third, in our laboratory, we have detected the presence of LGF in rat plasma after injection of dimethylnitrosamine or thioacetamide, and we have observed that higher levels of LGF in plasma coincide with greater hepatic necrosis (J. J. Diaz-Gil et al., unpublished work) . This could be interpreted as the regeneration wave that follows liver necrosis to repair the damage.
This model may be applicable to other species. In this context, we have detected a liver DNA synthesis promoter activity in human plasma from patients with hepatitis, with apparently the same characteristics as LGF (Diaz-Gil et al., 1986b) . On the other hand, some authors (Weiss et al., 1983; Seligson et al., 1985) described a special kind of albumin-bilirubin complex, called biliprotein, only detected in pathological states of the liver. This abnormal product of bilirubin metabolism could be the counterpart, in humans, of rat LGF.
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